Bright Minds Biosciences Inc. - common stock (DRUG)
DRUG moved a median of 0.00% 30 minutes after news, and -0.04% by the close. How DRUG actually reacts to news — the realized, point-in-time move the market made, measured across 134 labeled events over the last three years with zero look-ahead.
DRUG’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 120 |
| 30-min | 0.00% | 49% | 132 |
| 60-min | 0.00% | 48% | 133 |
| to close | -0.04% | 48% | 133 |
| Middle 50% of DRUG reactions | -2.22% to +2.10% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 134 |
Half of all Bright Minds Biosciences Inc. - common stock news events land between -2.22% and +2.10% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How DRUG reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 26 | -1.41% | 15% | -5.20% |
| Rating reiterations | 30 | -0.50% | 30% | -0.75% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how DRUG ranks against every other measured name →
That’s how DRUG usually reacts — get an email when it moves on news →Email me when DRUG moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DRUG's baseline. Nothing else.
Recent DRUG events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +0.02% | -1.77% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | +3.15% | -0.67% | |
| Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference | Press release | GlobeNewswire | +3.15% | -0.67% | |
| Bright Minds Biosciences to Present at Upcoming Conferences | Press release | GlobeNewswire | +0.24% | +2.83% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.22% | +4.00% | |
| Form S-8 BRIGHT MINDS BIOSCIENCES | SEC filing · Form S-8 | SEC EDGAR | -0.75% | -2.80% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +0.61% | -1.61% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Jan 20 | SEC filing · Form 6-K | SEC EDGAR | -0.78% | +0.38% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: May 26 | SEC filing · Form 6-K | SEC EDGAR | +0.06% | +3.16% | |
| Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +1.66% | +0.56% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +0.07% | +7.52% | |
| Bright Minds Biosciences to Present at Upcoming Conferences | Press release | GlobeNewswire | +0.00% | -5.99% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -3.63% | |
| Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | Press release | GlobeNewswire | — | -2.63% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Jan 07 | SEC filing · Form 6-K | SEC EDGAR | -0.04% | -3.74% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Jan 09 | SEC filing · Form 6-K | SEC EDGAR | -2.16% | -0.18% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Jan 07 | SEC filing · Form 6-K | SEC EDGAR | -3.25% | -5.87% | |
| Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock | Press release | GlobeNewswire | -3.25% | -5.87% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Jan 06 | SEC filing · Form 6-K | SEC EDGAR | -0.88% | +4.74% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Jan 07 | SEC filing · Form 6-K | SEC EDGAR | -3.25% | -5.87% | |
| Bright Minds Biosciences Announces Launch of US$100 Million Public Offering | Press release | GlobeNewswire | -0.88% | +4.74% | |
| Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) | Press release | GlobeNewswire | -7.54% | -22.20% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Jan 06 | SEC filing · Form 6-K | SEC EDGAR | -0.88% | +4.74% | |
| Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 | Press release | GlobeNewswire | -7.54% | -22.20% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Jan 05 | SEC filing · Form 6-K | SEC EDGAR | -7.54% | -22.20% | |
| Form 40-F BRIGHT MINDS BIOSCIENCES For: Sep 30 | SEC filing · Form 40-F | SEC EDGAR | +0.38% | +0.39% | |
| Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting | Press release | GlobeNewswire | -2.65% | +0.64% | |
| Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) | Press release | GlobeNewswire | -0.02% | +0.29% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Nov 17 | SEC filing · Form 6-K | SEC EDGAR | +0.67% | +1.09% | |
| Form 6-K/A BRIGHT MINDS BIOSCIENCES For: Nov 06 | SEC filing · Form 6-K | SEC EDGAR | +0.98% | +0.98% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Nov 06 | SEC filing · Form 6-K | SEC EDGAR | +0.40% | +0.51% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Oct 30 | SEC filing · Form 6-K | SEC EDGAR | +0.40% | +0.51% | |
| Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH | Press release | GlobeNewswire | +2.15% | +7.63% | |
| Bright Minds Biosciences to Present at Upcoming Conferences | Press release | GlobeNewswire | +0.00% | +0.63% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Sep 04 | SEC filing · Form 6-K | SEC EDGAR | -0.02% | -2.06% | |
| BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING | Press release | Canada Newswire | -0.02% | -2.06% | |
| Bright Minds Biosciences Announces BMB-201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model | Press release | GlobeNewswire | +3.90% | -1.57% | |
| Form EFFECT BRIGHT MINDS BIOSCIENCES | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +13.18% | |
| Form F-3 BRIGHT MINDS BIOSCIENCES | SEC filing · Form F-3 | SEC EDGAR | +4.67% | +8.90% | |
| Bright Minds Biosciences to Present at Upcoming Conferences | Press release | GlobeNewswire | +0.00% | -5.61% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.11% | -3.71% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -0.60% | +2.79% | |
| Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +6.30% | -0.55% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: May 28 | SEC filing · Form 6-K | SEC EDGAR | — | -0.85% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: May 20 | SEC filing · Form 6-K | SEC EDGAR | — | -3.82% | |
| Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 | Press release | GlobeNewswire | -2.27% | +1.44% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: May 13 | SEC filing · Form 6-K | SEC EDGAR | +0.98% | -1.77% | |
| Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 | Press release | GlobeNewswire | +2.29% | -9.04% | |
| Form 6-K BRIGHT MINDS BIOSCIENCES For: Apr 28 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -6.73% | |
| Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study | Press release | GlobeNewswire | +0.00% | -2.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DRUG section they belong to.
Where else DRUG is measured.
DRUG earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Bright Minds Biosciences Inc. - common stock's median reaction calculated?
Every labeled DRUG news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 134 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of DRUG's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DRUG's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.